Unlocking Future of Large and Small Molecule Pharma R&D with Science-Driven Digital Solutions

As pharmaceutical companies expand their R&D operations globally, Indian Contract Development and Manufacturing Organisations (CDMOs) are attracting significant investment.

- 

In recent years, India has emerged as a leader in the production of generic small molecules. In 2023, the India small molecule CDMO market generated a revenue of $6.8 billion, and a compound growth rate of 9 per cent is expected by 2030. However, large molecules, also known as biologics, are now also taking root. Attracting considerable investment, the development of biologics and biosimilars (highly similar copies of approved biologics) is creating new streams of revenue generation in India. The Indian large molecule CDMO market is set to double over the next few years, from a revenue of just below $1 billion in 2023 to $2 billion by 2030.

Key Digital Technologies Empowering Pharma R&D

Digital transformation has become a cornerstone for advancing pharmaceutical R&D over the last few years. By integrating advanced digital platforms, pharma companies can reduce costs, increase response time, enhance stakeholder communication, and create robust chains of identity and custody. These digital tools also deliver new insights that were previously unavailable, providing data that helps executives drive continuous improvement. Given the global nature of the industry, digital platforms are now essential for both efficiency and scalability.

The technological revolution in drug discovery has generated vast and complex datasets, which can be mined and analysed for multiple purposes. To make this possible, digital platforms that can aggregate R&D data from multiple sources and then provide a unified resource that can be analysed and interpreted will offer significant competitive advantage, helping streamline drug development from discovery through to market.